RecruitingNot ApplicableNCT05887102

Pilot Study of PACHA Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors

Pilot Study of a Community Pharmacy-Based Program to Enhance Adherence to Adjuvant Endocrine Therapy Among Breast Cancer Survivors


Sponsor

CHU de Quebec-Universite Laval

Enrollment

66 participants

Start Date

Jun 7, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this randomized controlled pilot study is to assess the feasibility, acceptability, and preliminary effects of the PACHA program designed for women having an adjuvant endocrine therapy (AET) after hormone-sensitive breast cancer. PACHA (programme en Pharmacie pour l'ACcompagnement des femmes ayant de l'Hormonothérapie Adjuvante) is a community pharmacy-based program aimed at optimizing the experience of AET and its use. The main questions it aims to answer are : * Does the program have an effect on factors expected to influence AET adherence? * Is the program acceptable? * Is the implementation of the program feasible? * What is the feasibility of procedures for carrying out a full-scale study? Participating community pharmacies will be randomized. Pharmacists working in pharmacies assigned to the PACHA group (33 pharmacies) will receive web-based training and manuals to use during their consultations with women having an AET. Recruited women attending these pharmacies will also have access to information and resources about AET (videos, evidence-based booklet). Pharmacists practicing in pharmacies assigned to the control group (33 pharmacies) will provide usual care.


Eligibility

Min Age: 18 Years

Inclusion Criteria14

  • For pharmacies :
  • In the province of Quebec, Canada
  • At least one pharmacist agrees to take charge of the project in their pharmacy
  • At least one women has initiated adjuvant endocrine therapy (AET) in the last 6 months in the pharmacy
  • For pharmacists :
  • Practicing in a pharmacy in the province of Quebec
  • Provide consent
  • For women :
  • years old or older
  • Were diagnosed with a first non-metastatic, hormone-sensitive breast cancer
  • Received and AET prescription for the first time in the last 6 months
  • Are fluent in French
  • Have internet access
  • Provide consent

Exclusion Criteria2

  • For women :
  • • Live in a residential facility where AET is not self-managed

Interventions

BEHAVIORALPACHA Program

Pharmacists in this group will complete the 85-minutes web-based training, schedule and realize at least 2 telephone consultations with participating women in their pharmacy (in the first month and 4 months after randomization) using standardized consultation guides based on the principles of motivational interviewing and, if necessary, the evidence-based web sheets about strategies to cope with side effects and other AET-related concerns. Women in this group will have access to a web site that includes video capsules to inform women about AET, evidence-based web sheets describing strategies to cope with side effects and other AET-related concerns, testimonies of women who had breast cancer and an AET and a list of resources available for women.


Locations(1)

Centre de recherche du CHU de Québec

Québec, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05887102


Related Trials